Human immunoglobulin allotypes: possible implications for immunogenicity - Wikidata - wikimedia - TriplyDB

Human immunoglobulin allotypes: possible implications for immunogenicity

Human immunoglobulin allotypes: possible implications for immunogenicity

http://www.wikidata.org/entity/Q24651893

about

Therapeutic antibodies, vaccines and antibodyomes Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Posttranslational Modifications and the Immunogenicity of Biotherapeutics Targeting the Fc receptor in autoimmune disease IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence Immunogenetics as a tool in anthropological studies Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange.IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.Advancing Public Health Using Regulatory Science to Enhance Development and Regulation of Medical Products: Food and Drug Administration Research at the Center for Biologics Evaluation and Research Detecting low level sequence variants in recombinant monoclonal antibodies IgG subclasses and allotypes: from structure to effector functions.IMGT®, the international ImMunoGeneTics information system® 25 years on.Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study Immunoglobulins: 25 years of immunoinformatics and IMGT-ONTOLOGY.Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody.The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.Medicinal chemistry for 2020 Isolation of Foreign Material-Free Endothelial Progenitor Cells Using CD31 Aptamer and Therapeutic Application for Ischemic Injury.Epistatic interactions between Fc (GM) and FcγR genes and the host control of human immunodeficiency virus replication.Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.Pre-existing Antibody: Biotherapeutic Modality-Based Review.Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation.Glycoproteomic analysis of antibodies.Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis.Interactive Effects of Immunoglobulin Gamma and Human Leucocyte Antigen Genotypes on Response to Interferon Based Therapy of Hepatitis C Virus.A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.Identification of biomarkers for periodontal disease using the immunoproteomics approach.Immunoglobulin and T Cell Receptor Genes: IMGT(®) and the Birth and Rise of Immunoinformatics.Stability of IgG isotypes in serum.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Construction and characterization of a camelized, human, VH-based peptide vaccine against CD20 antigen.

P2860

Q24599662-0026CECD-2F48-4235-B58D-CA5F8CE97324 Q26738810-BE7F5DAC-AD81-4ABC-9BBF-8E10A942BA1D Q26748614-A679CBFC-4FE1-4D2D-866B-39CCE23E9892 Q27002843-E6E7ACAC-6C95-4F79-8464-3CFD390F1F48 Q28545233-A2D0EFD8-4794-4FBB-8946-528D8996DDE3 Q28740417-22B6CB8D-0C23-49E5-A61C-606AB646FB9C Q30357905-5EBA2A4A-315D-4D24-85D0-4D4D1291B845 Q33600922-4523E1A3-0878-4757-89C3-C12B30045C83 Q33785803-B1023334-096A-44A2-95A3-DE0F46957232 Q33895815-4D90EC4B-362F-4526-BE68-DEE71432D87E Q34368678-9B3BDA9E-C15D-4A2A-9200-4AFE3E20F4AC Q34446760-3E24F601-C0CA-4B5B-8168-2566E1866C3D Q34614053-CB23B80D-F47C-4C42-AC0B-889131525719 Q34785812-A52691DD-D472-4024-BF2D-65BF24C8A7A4 Q35068156-1D070FF9-EA62-455D-B69C-5BD142BB0510 Q35221593-894823ED-60FC-42A2-B858-598621CA4198 Q35232337-109EC8C5-FA6D-4FC0-A723-AE39AE93ABCF Q35544546-1C0E2323-2033-4070-BBDA-E7EE5715DB74 Q35583369-93F11E05-820C-4430-8F96-65B84C329305 Q35587248-E3CB2511-B6CC-48EE-A95A-80F54CE09914 Q35593223-67430CE9-9BB5-457B-89D9-2F0B39F9BE8B Q35684128-29419549-CDBC-4128-9D9B-A67C5EEB5C29 Q35785518-D676475F-7041-4B60-A388-0E16A2B3AD3E Q36034526-50FA0E15-E517-443C-A054-5EA3D84D1842 Q36127055-A3638386-6DAD-47DE-9332-26EF722F461B Q36213182-CA64307C-B3A0-4536-B558-9518E1B9D729 Q36214720-4AB93D7D-CCFF-4B43-96EB-D81FDAC0740D Q36223471-BD3FB3F9-2A6A-4D39-A481-DE190FCE41A5 Q36653888-382A1453-DC4A-4618-AE29-83B0C8FB8835 Q36725918-B6DD2CB9-E556-48A4-A3E0-5BB96D1AAD0E Q36742404-3A92272D-378D-4A0B-8756-17AC2EA6C19D Q36866321-AAA652A2-5DE0-449A-A94F-A94C5095E7FF Q36929310-EF2722DC-334B-4F38-ABEF-275A65336FE3 Q37138449-E5B16EDC-46E9-4B90-9AC8-6D1722C70774 Q37234167-19FB22F4-FCEE-40EF-988C-26485925A2DE Q37555165-5BB42156-3D38-42CA-9A58-44EB4BEE108B Q37734089-BDB32EC1-5FA5-4EB7-95BE-26EF3F74606A Q38048706-5A80F601-8FFF-4C20-9FE5-A321049F21A7 Q38798420-AC70C2D6-4533-4C35-A6E2-BCC087B0233C Q39193766-285E0DD7-CC7C-4935-8A98-CEBBC14CD59F

P2860

Human immunoglobulin allotypes: possible implications for immunogenicity

http://www.wikidata.org/entity/Q24651893

description

2009 nî lūn-bûn

@nan

2009 թուականին հրատարակուած գիտական յօդուած

@hyw

2009 թվականին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Human immunoglobulin allotypes: possible implications for immunogenicity

@ast

Human immunoglobulin allotypes: possible implications for immunogenicity

@en

Human immunoglobulin allotypes: possible implications for immunogenicity

@nl

type

label

Human immunoglobulin allotypes: possible implications for immunogenicity

@ast

Human immunoglobulin allotypes: possible implications for immunogenicity

@en

Human immunoglobulin allotypes: possible implications for immunogenicity

@nl

prefLabel

Human immunoglobulin allotypes: possible implications for immunogenicity

@ast

Human immunoglobulin allotypes: possible implications for immunogenicity

@en

Human immunoglobulin allotypes: possible implications for immunogenicity

@nl

P1433

Q24651893-D902A5F1-B88C-44F9-A8A8-46DD9C49C8D7

P1476

Q24651893-3C7DD743-74DE-4A0D-ACEB-6F6A498A6B54

P2093

Q24651893-ABD530F5-7EFE-498F-8C48-E09EE9FF4CA2

P2860

Q24651893-0E55DDF7-BD60-49AF-AC13-55E845AB1C5F

Q24651893-15CAE073-E896-4FD9-8169-F577FC8560BD

Q24651893-232A5161-E276-439E-9771-78E048AD981B

Q24651893-3532437A-7C7A-4103-B1E3-E9F45BA05EF6

Q24651893-3A6B651D-C98B-422D-AE17-BC7BCA1B91F9

Q24651893-3DAACB38-3A38-4E93-A152-C8D88228BEC3

Q24651893-3EDE5118-1C62-4E92-B9B5-32A60FC90EC0

Q24651893-4C852411-711A-4A8A-BA3D-B01C9012EA5F

Q24651893-4EDE178B-B869-462D-AAE0-E3C4EC068221

Q24651893-550C8889-F645-4FAC-8237-B7D1F843A856

P304

Q24651893-980501E7-A410-423B-9B58-CF6EBDDC6A60

P31

Q24651893-D47FD729-2470-4763-8C6B-73FB64C08839

P3181

Q24651893-7272DE41-5E6B-4B0B-9102-D7357D979AF0

P356

Q24651893-3455BEF2-07AC-4350-9853-C933D7CBD58C

P407

Q24651893-6D55EA1F-681E-441D-B766-233ED4BC715E

P433

Q24651893-29FB76FE-ABD9-4746-88A2-E8C9FDD817FB

P478

Q24651893-14F2A7C3-4E31-4104-8D66-3AB5D29EE273

P50

Q24651893-E2E2CC61-1174-4F1D-880C-18A7532ECC73

P577

Q24651893-03A04A64-E765-49A5-BF35-E2DC65D6A786

P5875

Q24651893-C1AC3454-26F0-4DFF-8FD7-592BE12A4F3D

P698

Q24651893-A7D64DF7-D486-4F5C-AED3-FCAF0F617DA8

P932

Q24651893-3B14E053-0AE1-4867-94DD-732718781343

P3181

P356

P1433

Monoclonal Antibodies

P1476

Human immunoglobulin allotypes: possible implications for immunogenicity

@en

P2093

Roy Jefferis

http://www.w3.org/2001/XMLSchema#string

P2860

IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes

Humanization of an anti-p185HER2 antibody for human cancer therapy

GM and KM immunoglobulin allotypes in the Galician population: new insights into the peopling of the Iberian Peninsula

Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions

Human antibody-Fc receptor interactions illuminated by crystal structures

The first constant-domain (CH1) exon of human IGHG2 is polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n+) allotype in Caucasians.

Immunoglobulin GM and KM allotypes and vaccine immunity.

Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria

Human immunoglobulin C lambda 6 gene encodes the Kern+Oz-lambda chain and C lambda 4 and C lambda 5 are pseudogenes.

Interactions of immunoglobulins outside the antigen-combining site.

P304

332-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

418475

http://www.w3.org/2001/XMLSchema#string

P356

10.4161/MABS.1.4.9122

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Paule Lefranc

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41026599

http://www.w3.org/2001/XMLSchema#string

P698

20073133

http://www.w3.org/2001/XMLSchema#string

P932

2726606

http://www.w3.org/2001/XMLSchema#string